Uwe Dr. Schönrock
Beiersdorf
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Uwe Dr. Schönrock.
Archives of Dermatological Research | 2006
Ludger Kolbe; Jeannine Immeyer; Jan Batzer; Ursula Wensorra; Karen Torn Dieck; Claudia Mundt; Rainer Wolber; Franz Stäb; Uwe Dr. Schönrock; Roger I. Ceilley; Horst Wenck
Licochalcone A (LicA), a major phenolic constituent of the licorice species Glycyrrhiza inflata, has recently been reported to have anti-inflammatory as well as anti-microbial effects. These anti-inflammatory properties might be exploited for topical applications of LicA. We conducted prospective randomized vehicle-controlled clinical trials to assess the anti-irritative efficacy of cosmetic formulations containing LicA in a post-shaving skin irritation model and on UV-induced erythema formation. The clinical trials were accompanied by a series of in vitro experiments to characterize anti-inflammatory properties of LicA on several dermatologically relevant cell types. Topical LicA causes a highly significant reduction in erythema relative to the vehicle control in both the shave- and UV-induced erythema tests, demonstrating the anti-irritative properties of LicA. Furthermore, LicA is a potent inhibitor of pro-inflammatory in vitro responses, including N-formyl-MET-LEU-PHE (fMLP)- or zymosan-induced oxidative burst of granulocytes, UVB-induced PGE2 release by keratinocytes, lipopolysaccharide (LPS)-induced PGE2 release by adult dermal fibroblasts, fMLP-induced LTB4 release by granulocytes, and LPS-induced IL-6/TNF-α secretion by monocyte-derived dendritic cells. The reported data suggest therapeutic skin care benefits from LicA when applied to sensitive or irritated skin.
European Journal of Pharmaceutics and Biopharmaceutics | 2003
T. Rode; M. Frauen; Bernd W. Müller; H.J. Düsing; Uwe Dr. Schönrock; Claudia Mundt; Horst Wenck
The main objective of this study was to devise novel methods for improving the solubility of the anti-inflammatory triterpenoid sericoside, the main component of Terminalia sericea extract, thus enabling its incorporation into topical formulations. Sericoside was stabilized by complex formation with hydrophilic derivatives of beta- and gamma-cyclodextrins in a molar ratio of 1.0:1.1. The complex of extract and cyclodextrin was equilibrated in water at 25 degrees C for approximately 24 h. The dehydrated complexes of T. sericea extract and cyclodextrin were characterized by differential scanning calorimetry, thermogravimetry analysis and X-ray diffraction. Complex formation with beta-cyclodextrin as well as gamma-cyclodextrin derivatives was detectable using these three analytical tools; however, only complexes with gamma-cyclodextrin derivatives showed stability upon storage after incorporation into topical o/w or w/o formulations. Furthermore, a T. sericea extract/gamma-cyclodextrin complex incorporated in an o/w formulation resulted in a 2.6-fold higher percutaneous penetration of sericoside in in vitro excised pig skin as compared to pure T. sericea extract. For the first time, the virtually insoluble anti-inflammatory active sericoside was incorporated into a topical emulsion based formulation in a stable manner, resulting in efficient skin penetration.
Archive | 1999
Uwe Dr. Schönrock; Inge Kruse
Archive | 1993
Gerhard Sauermann; Uwe Dr. Schönrock; Volker Schreiner; Franz Stäb
Archive | 1999
Uwe Dr. Schönrock; Heiner Max
Archive | 1997
Uwe Dr. Schönrock; Friedhelm Steckel; Ulrich Kux; Kazuo Inoue
Archive | 2002
Jan Batzer; Werner Berens; Thomas Blatt; Reza Keyhani; Inge Kruse; Claudia Mundt; Andreas Schepky; Melanie Schmidt; Uwe Dr. Schönrock; Jens Schulz; Christoph Smuda; Franz Stäb; Rainer Wolber
Archive | 1995
Dorte Artz; Michael Christiansen; Uwe Dr. Schönrock; Sigrid Steinke
Archive | 1999
Uwe Dr. Schönrock; Heiner Max
Archive | 1999
Volker Schreiner; Uwe Dr. Schönrock; Franz Stäb; Heiner Max; Konrad Sandhoff; Thomas Döring